Korea Exchange · Healthcare
Samil Pharmaceutical stock from India: price, numbers and tax
Samil Pharmaceutical (000520) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Samil Pharmaceutical at a glance
- Price
- ₩8,350.00-₩180.00 (2.11%)
- Market cap
- ₩178.44B
- Day range
- ₩8,280.00 – ₩8,560.00
- P/E
- -4.73
- Dividend yield
- None
- Volume
- 47.47K
- 1 month
- +19.46%
- 6 months
- -11.08%
- YTD
- -13.83%
- 1 year
- -17.08%
- 5 years
- +9.35%
Samil Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩210.4B | ₩219.7B | ₩196.3B | ₩179.7B | ₩134.2B |
| Gross profit | ₩67.4B | ₩80.9B | ₩72.2B | ₩67.5B | ₩49.0B |
| Operating income | −₩23.9B | ₩113.0M | ₩6.5B | ₩4.0B | ₩399.7M |
| Net income | −₩34.6B | −₩5.6B | ₩1.7B | −₩28.3M | −₩5.3B |
| Earnings per share | −₩1,627.95 | −₩313.00 | ₩116.16 | −₩2.03 | −₩386.63 |
| EBITDA | −₩10.7B | ₩8.7B | ₩10.3B | ₩10.3B | ₩6.2B |
| Total assets | ₩371.6B | ₩395.1B | ₩370.7B | ₩356.7B | ₩226.4B |
| Total debt | ₩164.0B | ₩150.1B | ₩175.9B | ₩159.3B | ₩125.5B |
| Cash and short-term investments | ₩6.4B | ₩5.1B | ₩906.1M | ₩1.9B | ₩15.3B |
| Shareholders' equity | ₩133.3B | ₩176.1B | ₩127.8B | ₩125.8B | ₩65.7B |
| Operating cash flow | −₩6.1B | ₩2.6B | ₩11.7B | ₩4.2B | ₩1.4B |
| Free cash flow | −₩13.5B | −₩3.0B | −₩12.6B | −₩44.5B | −₩31.7B |
| Capital expenditure | −₩7.5B | −₩5.6B | −₩24.4B | −₩48.7B | −₩33.1B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Yuhan | 000100.KS | ₩73,100.00 | ₩5.38T |
| Dong-A Socio | 000640.KS | ₩93,000.00 | ₩626.13B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Ildong | 000230.KS | ₩6,160.00 | ₩71.09B |
| Yuyu Pharma | 000220.KS | ₩3,840.00 | ₩60.47B |
| Hims & Hers Health | HIMS | $30.92 | $6.90B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Samil Pharmaceutical from India
What Samil Pharmaceutical does
Samil Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company founded in 1947 that develops, manufactures, and sells a range of healthcare products. While its portfolio includes various medicines and medical devices, it has a particular specialization in ophthalmology (eye care). Samil Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Samil Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.